Table 1.

Demographic characteristics and anatomical follow-up parameters of Group 1 (management with only WJ-MSCs).

Patient no	Genetic mutation	Eye	Horizontal EZW		Vertical EZW		FAF field
			Time0	Time1	Time0	Time1	Time0	Time1
1	RHO	R	3.56	3.58	4.62	4.64	8.1	8.2
2	RP1	L	3.21	3.27	3.36	3.38	7.9	8.0
3	EYS	R	1.86	1.55	1.15	0.88	3.1	2.5
4	PCARE	L	3.93	3.39	2.72	2.02	8.2	6.6
5	RPGR	L	1.61	0.52	1.44	0.48	0.8	0.5
6	ABCA4	R	2.74	2.34	2.49	2.00	4.9	4.0
7	C2ORF	R	4.01	3.88	4.02	3.88	15.1	14.0
8	USH2A	L	2.61	2.61	2.45	2.45	4.8	4.8
9	USH2A	L	3.91	3.90	3.92	3.90	14.9	14.8
10	RP1	L	3.90	3.47	3.86	3.43	12.2	10.4
11	PDE6B	R	3.87	3.34	3.71	3.20	9.9	8.0
12	USH2A	R	1.02	1.02	1.09	1.09	0.8	0.8
13	PDE6B	L	1.15	0.84	1.13	0.82	1.0	0.7
14	MERTK	R	2.23	1.88	2.08	1.65	3.8	2.4
15	PRPF3	L	2.18	2.18	2.14	2.14	4.1	4.1
16	RPGR	R	2.18	1.20	2.14	1.16	4.0	2.2
17	PDE6B	L	2.90	2.30	1.32	0.81	2.8	1.6
18	TULP1	L	1.42	1.40	1.25	1.24	1.1	1.0
19	USH2A	R	2.11	2.12	3.03	3.04	5.6	5.6
20	PDE6B	R	1.11	0.89	1.14	0.91	1.0	0.7
21	BBS2	R	1.15	1.15	1.06	1.06	1.1	1.1
22	PRPF3	L	2.49	2.49	2.26	2.26	4.4	4.4
23	RP1	R	2.51	2.49	2.54	2.52	5.1	5.0
24	RHO	L	3.18	3.20	3.21	3.21	8.9	8.9
25	RHO	L	3.26	3.26	3.14	3.14	9.0	9.0
26	PRPF3	L	2.11	2.11	2.29	2.29	4.0	4.0
27	BBS6	L	1.78	1.76	1.66	1.65	1.2	1.1
28	USH2A	R	1.66	1.64	1.38	1.36	1.4	1.3
29	EYS	R	1.48	1.21	1.51	1.22	1.3	0.9
30	RHO	L	4.71	4.74	4.79	4.82	15.5	15.6
31	RHO	R	4.90	4.92	3.96	3.98	15.1	16.6
	RHO	L	4.71	4.72	4.00	4.01	15.6	16.6
32	CERKL	R	2.57	2.28	2.44	2.15	4.1	3.2
	CERKL	L	1.98	1.76	1.87	1.64	2.9	2.1

Time0 (baseline), just before the Wharton Jelly derived mesenchymal stem cell injection.

Time1: 36th month after injection.

Abbreviations: EZW, ellipsoid zone width (mm); FAF, fundus autofluorescence (mm²); WJ-MSCs, Wharton’s jelly derived mesenchymal stem cells.